Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on the release of study findings. Cybin sponsored the study, which was conducted by Kernel, a leader in noninvasive neuroimaging. Titled “Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS,” the study was published in “Scientific Reports from the Nature Portfolio of Journals” and evaluated the ability of Kernel’s Flow1 system to capture and analyze brain changes resulting from the administration of a psychoactive substance. According to the announcement, the single-blind, placebo-controlled study was the first fNIRS (“fNIRS”) human-neuroimaging study with ketamine ever conducted; the announcement also noted that it was the largest fNIRS study measuring the acute effect of a psychedelic.
The study represents a “significant milestone in the field of neuroimaging,” according to Kernel management, and demonstrated “the remarkable ease and capabilities of Flow1 to explore the physiological effects of psychedelics like ketamine in natural settings.” The company will use the study results to evaluate large-scale clinical study opportunities using its Flow technology. “The feasibility study is truly groundbreaking as it supports Kernel’s ability to measure functional brain activity in real time, using a wearable, convenient device,” said Cybin CEO Doug Drysdale in the press release. “The study results also suggest that a combination of metrics may be predictive of subjective mystical experiences during psychedelic treatment. We are excited about the potential for this technology in expanding our understanding of the mechanisms and effects of psychedelic-based therapeutics on the brain and applications to research and clinical trials, which is essential to Cybin’s goal of developing differentiated therapeutics for people with mental health conditions.”
To view the full press release, visit https://ibn.fm/3Aemp
About Cybin Inc.
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder; the company also has a research pipeline of investigational psychedelic-based compounds. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.